Literature DB >> 15491058

Fetal cell/tissue therapy in adult disease: a new horizon in regenerative medicine.

N Bhattacharya1.   

Abstract

Fetal tissue is the richest source of primordial stem cells and has several properties that make it particularly useful for transplantation. It is superior to adult (mature) tissue in certain respects. First, fetal cells are capable of proliferating faster and more often than mature, fully differentiated cells. This means that these donor cells are able to quickly reverse the lost function of the host. In addition, these fetal cells can often differentiate in response to the environmental cues around them. This is because of their location--they can grow, elongate, migrate, and establish functional connections with other cells around them in the host. It has been found that fetal tissue is not easily rejected by the recipient due to the low levels of histocompatibility antigens in the fetal tissue. At the same time, angiogenic and trophic factors are at high levels, enhancing their ability to grow once they are transplanted. Since early fetal hematopoietic tissue lacks lymphocytes, graft vs host reactions are minimized. Fetal cells tend to survive excision, dissection, and grafting better because they generally do not have long extensions or strong intercellular connections. Finally, fetal tissue can survive at lower oxygen levels than mature cells. This would make them more resistant to the ischemic conditions found during transplantation or in vitro situations. Studies on fetal cell/tissue transplant have been encouraging. Fetal tissue can be used in different indications, for instance, fetal liver transplants may be used in combating aplastic anemia, placental umbilical cord whole blood transfusion can serve as an emergency alternative to adult whole blood transfusion, fetal adrenal transplant has been tried in combating intractable pain in arthritis, and fetal thymic transplant in combating leucopenia in non-Hodgkin's lymhoma and other immunodeficiency conditions like DiGeorge Syndrome, only to name a few. Fetal brain tissue transplant has also been done in a heterotopic site and the proliferation of the tissue has been observed. Neurotransplantation with fetal tissue in Parkinsonism shows positive results in some globally accepted studies. There are futuristic potential uses of fetal tissue in bioengineering through coating/seedling of fetal tissue on implants, stents and other artificial surgical life-saving devices to improve their functioning, and it may also extend the life of these costly gadgets. By properly using pre-HLA fetal tissue seedling in orthopedic, thoracic and also neurosurgical appliances, there could be a reduction of long-term irritation sequelae of the implant and the host interphase, and thus, a better device, i.e., a more biofriendly interphase could be developed. This may help in the reduction of pseudomembrane formation, loss of patency and other resultant TH2 reactions of the host system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15491058

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  10 in total

1.  Fetal Tissues Tested for Microbial Sterility by Culture- and PCR-Based Methods Can be Safely Used in Clinics.

Authors:  Yakov Vitrenko; Iryna Kostenko; Kateryna Kulebyakina; Alla Duda; Mariya Klunnyk; Khrystyna Sorochynska
Journal:  Cell Transplant       Date:  2016-08-05       Impact factor: 4.064

2.  Swiss Fetal Transplantation Program and Non-enzymatically Isolated Primary Progenitor Cell Types for Regenerative Medicine.

Authors:  Alexis Laurent; Corinne Scaletta; Nathalie Hirt-Burri; Wassim Raffoul; Anthony S de Buys Roessingh; Lee Ann Applegate
Journal:  Methods Mol Biol       Date:  2021

3.  Human muscular fetal cells: a potential cell source for muscular therapies.

Authors:  Nathalie Hirt-Burri; Anthony S de Buys Roessingh; Corinne Scaletta; Stefan Gerber; Dominique P Pioletti; Lee Ann Applegate; Judith Hohlfeld
Journal:  Pediatr Surg Int       Date:  2008-01       Impact factor: 1.827

4.  The effect of source animal age upon the in vivo remodeling characteristics of an extracellular matrix scaffold.

Authors:  Brian M Sicari; Scott A Johnson; Bernard F Siu; Peter M Crapo; Kerry A Daly; Hongbin Jiang; Christopher J Medberry; Stephen Tottey; Neill J Turner; Stephen F Badylak
Journal:  Biomaterials       Date:  2012-05-09       Impact factor: 12.479

5.  Bioimprinted polymer platforms for cell culture using soft lithography.

Authors:  Lynn M Murray; Volker Nock; John J Evans; Maan M Alkaisi
Journal:  J Nanobiotechnology       Date:  2014-12-30       Impact factor: 10.435

6.  Retrospective Evaluation of Progenitor Biological Bandage Use: A Complementary and Safe Therapeutic Management Option for Prevention of Hypertrophic Scarring in Pediatric Burn Care.

Authors:  Karim Al-Dourobi; Alexis Laurent; Lina Deghayli; Marjorie Flahaut; Philippe Abdel-Sayed; Corinne Scaletta; Murielle Michetti; Laurent Waselle; Jeanne-Pascale Simon; Oumama El Ezzi; Wassim Raffoul; Lee Ann Applegate; Nathalie Hirt-Burri; Anthony S de Buys Roessingh
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-28

7.  Prevalence of human pegivirus-1 and sequence variability of its E2 glycoprotein estimated from screening donors of fetal stem cell-containing material.

Authors:  Yakov Vitrenko; Iryna Kostenko; Kateryna Kulebyakina; Khrystyna Sorochynska
Journal:  Virol J       Date:  2017-08-31       Impact factor: 4.099

8.  Engrafting fetal liver cells into multiple tissues of healthy adult mice without the use of immunosuppressants.

Authors:  Adas Darinskas; Renata Gasparaviciute; Mantas Malisauskas; Kristina Wilhelm; Jurij A Kozhevnikov; Evaldas Liutkevicius; Audrone Pilinkiene; Ludmilla A Morozova-Roche
Journal:  Cell Mol Biol Lett       Date:  2007-05-10       Impact factor: 5.787

9.  Holistic Approach of Swiss Fetal Progenitor Cell Banking: Optimizing Safe and Sustainable Substrates for Regenerative Medicine and Biotechnology.

Authors:  Alexis Laurent; Nathalie Hirt-Burri; Corinne Scaletta; Murielle Michetti; Anthony S de Buys Roessingh; Wassim Raffoul; Lee Ann Applegate
Journal:  Front Bioeng Biotechnol       Date:  2020-10-23

10.  Back to the Cradle of Cytotherapy: Integrating a Century of Clinical Research and Biotechnology-Based Manufacturing for Modern Tissue-Specific Cellular Treatments in Switzerland.

Authors:  Alexis Laurent; Philippe Abdel-Sayed; Corinne Scaletta; Philippe Laurent; Elénie Laurent; Murielle Michetti; Anthony de Buys Roessingh; Wassim Raffoul; Nathalie Hirt-Burri; Lee Ann Applegate
Journal:  Bioengineering (Basel)       Date:  2021-12-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.